About Arnigeno Life Sciences Private Limited
Data last updated:
Arnigeno Life Sciences Private Limited is a private limited company based in Thane, Maharashtra, India, recognised as a startup by DPIIT. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 07 July 2020 and has been in existence for over 6 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U51909MH2020PTC341546. Its GSTIN is 23AATCA6452A1ZV (Madhya Pradesh).
The company has an authorised share capital of ₹3 Lakh and a paid-up capital of ₹3 Lakh. It is led by directors including Arti Chouksey and Anita Chouksey.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 802 Prathmesh Heritage Tower 2 Kanakia Road Beverly Park Mira Road, Thane, Maharashtra, India – 401107.
As per the financials filed for FY 2025, the company reported a revenue of ₹29.93 Lakh, a growth of 35% compared to the previous year. For the same year it recorded a net profit of ₹23,990 (net margin 0.8%) and EBITDA of ₹2.66 Lakh (EBITDA margin 8.9%). Revenue has grown at a compounded annual rate (CAGR) of 8% over three years.
For more details, the company can be reached via its website arnigenolifesciences.com.
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social MediaLocked
- Registered Address802 Prathmesh Heritage Tower 2 Kanakia Road Beverly Park Mira Road, Thane, Maharashtra, India – 401107
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Arnigeno Life Sciences Private Limited
The main business activity of Arnigeno Life Sciences is wholesale and retail trade; repair of motor vehicles and motorcycles. In detail, this covers wholesale and retail trade and repair of motor vehicles and motorcycles.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Wholesale and retail trade; repair of motor vehicles and motorcycles | 45 | Wholesale and retail trade and repair of motor vehicles and motorcycles | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Arnigeno Life Sciences Private Limited FY 2025 filings available
Arnigeno Life Sciences Private Limited reported revenue of ₹29.93 Lakh (up 35% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Arnigeno Life Sciences Private Limited
Revenue has grown at a compounded annual rate (CAGR) of 8% over three years, including 35% growth in the latest year. EBITDA fell 25% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Arnigeno Life Sciences Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹2.66 Lakh | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹23,990 | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Arnigeno Life Sciences Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 8.9% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 0.8% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Arnigeno Life Sciences are in the company report.
Financial statements from FY 2021
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Arnigeno Life Sciences Private Limited
Arnigeno Life Sciences Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Sava Medica Limited | ₹30.21 Lakh (FY 2024) | •••• | •••• | •••• | Wadhwan, Gujarat, India | |
| Thebes Pharmaceuticals Private Limited | ₹30.2 Lakh (FY 2025) | •••• | •••• | 58.0% | •••• | New Delhi, Delhi, India |
| Sarosh Pharmaceuticals Private Limited | ₹30.04 Lakh (FY 2025) | •••• | •••• | 0.0% | •••• | Bahraich, Uttar Pradesh, India |
| Accufine Pharmaceuticals Private Limited | ₹30 Lakh (FY 2025) | •••• | •••• | •••• | Ahmedabad, Gujarat, India | |
| Floare & Zuvaka Global Pharma Private Limited | ₹29.95 Lakh (FY 2025) | •••• | •••• | 188.0% | •••• | Greater Noida, Uttar Pradesh, India |
| Arnigeno Life Sciences Private Limited this company | ₹29.93 Lakh (FY 2025) | •••• | •••• | 35.0% | •••• | Thane, Maharashtra, India |
| Vera Pharma Private Limited | ₹29.89 Lakh (FY 2025) | •••• | •••• | -39.0% | •••• | Thane, Maharashtra, India |
| Arretta Pharmaceuticals Private Limited | ₹29.77 Lakh (FY 2024) | •••• | •••• | -60.0% | •••• | Kandivali East Mumbai, Maharashtra, India |
| Speciality Formulations Private Limited | ₹29.7 Lakh (FY 2025) | •••• | •••• | -27.0% | •••• | Mumbai, Maharashtra, India |
| Trios Pharmaceuticals Private Limited | ₹29.68 Lakh (FY 2019) | •••• | •••• | -19.0% | •••• | New Delhi, Delhi, India |
| Mikado Laboratories Private Limited | ₹29.66 Lakh (FY 2025) | •••• | •••• | 8.0% | •••• | Mathura, Uttar Pradesh, India |
Peers are the five companies nearest above and the five nearest below Arnigeno Life Sciences by revenue in the Pharma industry (Formulations), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Board of Directors of Arnigeno Life Sciences Private Limited
Arnigeno Life Sciences has 3 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Arti Chouksey | Director | 07 Jul 2020 | 6 Years 3 Months | Current |
| Anita Chouksey | Director | 07 Jul 2020 | 6 Years 3 Months | Current |
| Ankit Kumar Gupta Also directs: Reclean Energy Private Limited | Director | 11 Feb 2026 | 0 Years 7 Months | Current |
Charges & Borrowings of Arnigeno Life Sciences Private Limited
Arnigeno Life Sciences Private Limited does not have any charges (loans) registered with the Registrar of Companies.
Employees and EPFO Compliance at Arnigeno Life Sciences Private Limited
Employment history and EPFO contributions of people linked to Arnigeno Life Sciences.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Arnigeno Life Sciences Private Limited
Arnigeno Life Sciences Private Limited has 3 board changes on record since 2020: 3 appointments. The latest: Ankit Kumar Gupta was appointed as Director on 11 Feb 2026.
Credit Ratings, Litigation & Regulatory Alerts for Arnigeno Life Sciences Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Arnigeno Life Sciences Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Arnigeno Life Sciences Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Arnigeno Life Sciences Private Limited
Arnigeno Life Sciences has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 23AATCA6452A1ZV | Madhya Pradesh | Active | 29 Sep 2020 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Arnigeno Life Sciences Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Arnigeno Life Sciences Private Limited
Arnigeno Life Sciences is an active private limited company based in Thane, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 07 July 2020 (6+ years old) and is registered under CIN U51909MH2020PTC341546.
Arnigeno Life Sciences reported revenue of ₹29.93 Lakh for FY 2025 (up 35% YoY).
Arnigeno Life Sciences has 3 current directors:
- Arti Chouksey - Director
- Anita Chouksey - Director
- Ankit Kumar Gupta - Director
Arnigeno Life Sciences reported a net profit of ₹23,990 (net margin 0.8%) and EBITDA of ₹2.66 Lakh (EBITDA margin 8.9%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Arnigeno Life Sciences is 8% over three years. In the latest year (FY 2025) revenue rose 35%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Arnigeno Life Sciences is 23AATCA6452A1ZV, registered in Madhya Pradesh.
The CIN (Corporate Identification Number) of Arnigeno Life Sciences is U51909MH2020PTC341546. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Arnigeno Life Sciences was incorporated on 07 July 2020, making it 6+ years old. It is registered with the Registrar of Companies, Mumbai.
The peers of Arnigeno Life Sciences by revenue are Sava Medica Limited, Thebes Pharmaceuticals Private Limited, Sarosh Pharmaceuticals Private Limited, Accufine Pharmaceuticals Private Limited, Floare & Zuvaka Global Pharma Private Limited and 5 more, all in the Pharma industry (Formulations).
Ankit Kumar Gupta was appointed as Director on 11 Feb 2026. Anita Chouksey was appointed as Director on 07 Jul 2020. Arti Chouksey was appointed as Director on 07 Jul 2020.
Yes, Arnigeno Life Sciences is recognised as a startup by the Department for Promotion of Industry and Internal Trade (DPIIT).